Augusto Mitidieri – Most Influential CEO Europe 2019 for Humancentric Driven Innovation

31 January 2020

Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award

31 January 2020

Helsinn Group Grants Exclusive Licensing Rights to Berlin-Chemie AG, a company of the Menarini Group, for ONICIT®/ALOXI® and AKYNZEO® in Russia and CIS region

27 January 2020

Progetto Talenti @ Zurich Life Science Day 2020

20 January 2020

Helsinn appoints Eric Cornut and Lonnie Moulder to the Board of Directors

13 January 2020

Helsinn to present a scientific poster on acute care use following CINV prophylaxis with agents in breast cancer patients at the San Antonio Breast Cancer Symposium (SABCS) 2019

16 December 2019

FDA grants Orphan Drug Designation to APR Applied Pharma Research’s Investigational Drug for the Treatment of Epidermolysis Bullosa

4 December 2019

3° trimestre 2019: industria farmaceutica ed energia guidano la crescita del PIL

28 November 2019

Helsinn Advanced Synthesis, Biasca: Reduces CO2 emissions by 80% and unveils the new anticancer plant

22 November 2019

Helsinn supported ‘70 Years of Cancer Care in China’ celebratory event in Shanghai

14 November 2019